Skip to main content
padlock icon - secure page this page is secure

Checkpoint inhibitors in Hodgkin's lymphoma

Buy Article:

$59.00 + tax (Refund Policy)

Hodgkin's lymphoma is unusual among cancers in that it consists of a small number of malignant Hodgkin/Reed–Sternberg cells in a sea of immune system cells, including T cells. Most of these T cells are reversibly inactivated in different ways and their reactivation may induce a very strong immune response to cancer cells. One way of reactivation of T cells is with antibodies blocking the CTLA‐4 and especially with antibodies directed against PD‐1 or the PD‐L1 ligand thereby reversing the tumor‐induced downregulation of T‐cell function and augmenting antitumor immune activity at the priming (CTLA‐4) or tissue effector (PD‐1) phase. Immune checkpoint inhibitors have been evidenced as an additional treatment option with substantial effectiveness and acceptable toxicity in heavily pretreated patients with Hodgkin's lymphoma. Particularly, PD‐1 blockade with nivolumab and pembrolizumab has demonstrated significant single‐agent activity in this select population.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Hodgkin's lymphoma; effectiveness; immune checkpoint inhibitors; toxicity

Document Type: Research Article

Publication date: April 1, 2016

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more